Clinical Trial

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 2, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-06-13; most recent amendment 2025-04-30.
Status change: Not Yet Recruiting → Recruiting 2025-04-20
Trial Details
NCT Number NCT03987308
Lead Sponsor Beijing Hospital
Conditions Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
Enrollment 115 participants
Start Date 2019-07-02
Primary Completion 2025-09 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-02